Teva JV Allows Takeda To Offload Mature Japan Portfolio
This article was originally published in PharmAsia News
Takeda is to transfer the bulk of its mature products in Japan into a new joint venture with Teva, in a move that will allow the Japanese firm to focus on its innovative portfolio while boosting the Israeli generic giant’s reach in Japan's fast-growing generics sector.
You may also be interested in...
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
After months of speculation and anticipation, Shionogi’s once-daily oral antiviral for the treatment of COVID-19 has stumbled after receiving an unexpected preliminary decision on its emergency approval from an advisory committee in Japan.